Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

515

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Fibrosis

Interventions

DRUG: placebo
DRUG: BIBF 1120

Sponsor

Boehringer Ingelheim